This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Subsequent myocardial infarction후속성 심근경색증

Contents and key points
ItemDetails
A. Classification codesICD-10: I22 (Subsequent myocardial infarction)  |  Special Copayment Reduction: V192 (Special Copayment Reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsRecurrent myocardial infarction, subsequent STEMI (I22.0: anterior wall, I22.1: inferior wall, I22.2: other), subsequent NSTEMI (I22.4), repeat myocardial infarction (subsequent AMI within 28 days of previous AMI)
C. Adult onsetSubsequent myocardial infarction is the occurrence of a new myocardial infarction in the same or a different region within 28 days after a previous myocardial infarction. Incomplete revascularization, nonadherence to antiplatelet therapy, and residual high-risk plaque are the main causes.
1. HistorySeparate classification as I22 in ICD-10 is recent. There was previously a clinical concept of 'reinfarction,' and recurrence rates decreased with the establishment of dual antiplatelet therapy in the 1990s–2000s. Currently, secondary prevention is strengthened with high-intensity statins and PCSK9 inhibitors.
2. CausesReocclusion of the previous infarct-related artery, new occlusion of a non-culprit artery in multivessel disease, stent thrombosis, discontinuation of antiplatelet therapy. Persistence of underlying high-risk conditions (diabetes, renal failure, multivessel disease) is the key cause.
3. GeneticsThe same CAD genetic basis as first myocardial infarction (GWAS risk variants, polygenic risk scores, FH genes). No independent genetic factor specific to recurrence has currently been identified. A drug metabolism gene (CYP2C19) affects the efficacy of clopidogrel.
4. General epidemiologyRecurrence rate within 1 year after first MI about 5~10%. Older age (>75 years), diabetes, chronic kidney disease, multivessel disease, and reduced LVEF are high-risk factors for recurrence. In Korean cohorts, 30-day mortality of recurrent MI is 2~3 times that of first MI.
5. PathophysiologyStent thrombosis (early: within 30 days; late: 30 days~1 year; very late: after 1 year), new plaque rupture in a non-culprit coronary artery, reinfarction of a residual ischemic region. Persistent platelet hyperreactivity is a promoting factor.
6. SymptomsChest pain and pressure similar to the first MI. However, because it occurs shortly after the first MI, symptoms may be masked while analgesics are in effect. Atypical symptoms (dyspnea, worsening fatigue) may be more common.
7. SignsSame as signs of the first MI. However, it often presents as worsening of existing heart failure. New ECG changes (ST elevation or new left bundle branch block) are key to diagnosis.
8. ScreeningRepeat ECG immediately when symptoms change during hospitalization for the first MI. Education to visit the emergency department immediately if symptoms recur after discharge. High-sensitivity troponin, echocardiography, and stress imaging used during outpatient follow-up.
9. DiagnosisDiagnosis of a new MI occurring within 28 days: re-elevation after troponin from the previous MI has fallen, new ECG changes. It may be difficult to distinguish existing from new Q waves. New wall motion abnormalities confirmed by echocardiography.
10. TreatmentSame principles as the first MI: immediate reperfusion (primary PCI first). For stent thrombosis, aspirin + ticagrelor (or IV cangrelor). If incomplete revascularization is the cause, consider PCI/CABG of residual lesions.
11. PrognosisMarkedly poorer than the first MI. 30-day mortality 2~3 times that of the first MI. Prognosis worsens cumulatively with more recurrences. High risk of cardiogenic shock and ventricular arrhythmias. Prognosis is worse with coexisting diabetes.
12. PreventionContinue DAPT (aspirin + ticagrelor or prasugrel) for 12 months. Achieve LDL <55mg/dL with high-intensity statin + PCSK9 inhibitor. Continue beta-blockers and ACE inhibitors. Cardiac rehabilitation. Management of medication adherence.
13. ReferencesWhen More Means Less: The Prognosis of Recurrent Acute Myocardial Infarctions (PMC, 2021) … and 9 other papers

1. History

Subsequent myocardial infarction (I22) is the occurrence of a new myocardial infarction in the same or a different coronary artery within 28 days after a previous acute myocardial infarction, and is classified separately in ICD-10. The clinical concept of 'reinfarction' has been recognized along with the early history of myocardial infarction treatment. In the thrombolytic era of the 1970s–80s, reinfarction after treatment was not uncommon, owing to incomplete initial thrombolysis and inadequate antiplatelet therapy.

With the U.S. FDA approval of ticlopidine in 1994 and the introduction of clopidogrel in 1997, dual antiplatelet therapy (DAPT) became standardized, and the risk of thrombosis and reinfarction after stenting decreased markedly. However, as the problem of variable efficacy due to CYP2C19 metabolic polymorphisms of clopidogrel emerged, the more potent P2Y12 inhibitors ticagrelor and prasugrel were introduced into standard ACS treatment in the 2010s. With second- and third-generation advances in drug-eluting stents (DES), the incidence of stent thrombosis fell dramatically but has not disappeared completely.

Since the 2010s, the advent of PCSK9 inhibitors has opened new possibilities for preventing recurrent myocardial infarction in very high-risk patients who do not reach LDL-C targets even with high-intensity statins. The FOURIER and ODYSSEY OUTCOMES trials demonstrated that PCSK9 inhibitors significantly reduce recurrent cardiovascular events in patients with prior myocardial infarction. Recently, the effect of colchicine in preventing cardiovascular recurrence through suppression of residual inflammation (LoDoCo2, COLCOT trials) is also being established. In this way, prevention strategies for subsequent myocardial infarction continue to evolve.


2. Causes

The causes of subsequent myocardial infarction are broadly divided into three. First is stent thrombosis, in which thrombus forms within a stent placed during previous PCI and the coronary artery reoccludes; it is classified as early stent thrombosis (within 30 days), late stent thrombosis (30 days~1 year), and very late stent thrombosis (more than 1 year). Premature discontinuation of antiplatelet therapy is the most important risk factor.

Second is new occlusion of a non-culprit coronary artery, in which an atherosclerotic plaque newly ruptures or erodes in a coronary artery different from the site of the previous myocardial infarction and thrombus forms. This risk is high in patients with multivessel disease when complete revascularization of non-culprit lesions has not been performed after the first myocardial infarction. Third is reocclusion of the previous infarct artery, in which the previous infarct site becomes blocked again due to incomplete reperfusion, stent malapposition, or the like.

Important underlying risk factors include diabetes (platelet hyperactivation, delayed vascular healing), chronic kidney disease (simultaneous increase in bleeding and thrombotic risk), complex coronary anatomy, left ventricular dysfunction, and older age. Poor adherence to antiplatelet agents is known to increase the risk of recurrent MI 2~3 times. The presence of residual high-risk plaque also contributes to short-term recurrence risk.


3. Genetics

The genetic basis of subsequent myocardial infarction shares the genetic factors of coronary artery disease (CAD) with first acute myocardial infarction. The 9p21.3 risk variant, PCSK9 gene variants, and familial hypercholesterolemia (FH)-related LDLR/APOB variants are involved in both first and recurrent myocardial infarction. No independent genetic factor specific to recurrence has been identified to date, but the usefulness of polygenic risk scores for predicting residual cardiovascular risk after a first MI is being studied.

From a pharmacogenetic standpoint, in patients with loss-of-function alleles of the CYP2C19 gene (poor metabolizer phenotype: *2, *3, etc.), conversion of clopidogrel to its active metabolite is reduced, so the platelet-inhibitory effect becomes insufficient and the risk of stent thrombosis and recurrent MI increases. On this basis, a tailored antiplatelet strategy of selecting ticagrelor or prasugrel instead of clopidogrel through CYP2C19 genetic testing is recommended in some guidelines (ACCF/AHA, 2023). There are also reports that PON1 gene polymorphisms are associated with clopidogrel responsiveness.


4. General epidemiology

Subsequent myocardial infarction is ICD-10 code I22, applied when a new AMI occurs within 28 days after a previous AMI (I21). The frequency of recurrent myocardial infarction within 1 year after a first MI is reported to be about 5~10% of all AMI patients, and lower than this when optimal medical therapy and complete revascularization have been achieved. In the long term, the annual recurrence rate in myocardial infarction survivors is about 2~4%.

Major risk factors for recurrent MI include ① older age (75 years or older), ② diabetes (1.5~2-fold increase in recurrence risk), ③ chronic kidney disease, ④ left ventricular dysfunction after myocardial infarction (LVEF <40%), ⑤ multivessel disease and incomplete revascularization, and ⑥ nonadherence to antiplatelet therapy. Korean cohort studies have also reported that the risk of recurrent MI is significantly higher in patients with diabetes than in those without, and that 30-day mortality of patients with recurrent MI is 2~3 times higher than for first MI. In women, especially elderly women, diagnostic delay due to atypical symptoms is a factor worsening clinical outcomes of recurrent MI.


5. Pathophysiology

The pathophysiology of subsequent myocardial infarction is understood through two main pathways. The first is stent thrombosis. When platelets are activated and coagulation proceeds within a stented coronary artery so that in-stent thrombus forms, abrupt reocclusion occurs. Early stent thrombosis (within 24 hours: acute; 24 hours~30 days: subacute) is mainly caused by stent malapposition, vascular anatomical abnormalities, and DAPT discontinuation. Polymer coatings of drug-eluting stents and in-stent neoatherosclerosis have been proposed as causes of late and very late stent thrombosis.

The second is occlusion of a non-culprit artery due to new plaque rupture. Besides the lesion that caused the first myocardial infarction, atherosclerosis is a systemic disease, and high-risk plaques exist in other coronary arteries as well. When a first MI occurs, vascular inflammation and a state of coagulation activation persist and can promote rupture of other unstable plaques (the concept of vulnerable blood, vulnerable plaque). When there is residual ischemia, especially with incomplete revascularization, recurrence is likely when physical or metabolic stress (tachycardia, elevated blood pressure, anemia) is added.


6. Symptoms

The symptoms of subsequent myocardial infarction are in principle the same as those of the first myocardial infarction. Severe precordial pressure, tightness, heaviness, radiating pain to the left arm, shoulder, and jaw, sweating, nausea, and dyspnea are typical symptoms. However, there are several reasons why clinical diagnosis is complicated. First, the effects of analgesics given in the acute phase of the previous myocardial infarction (opioid analgesics, ketorolac, etc.) may persist, reducing or masking symptoms. Second, when new ischemia occurs while cardiac function is already reduced by the previous myocardial infarction, it may present as dyspnea, worsening fatigue, or worsening heart failure symptoms rather than chest pain.

The proportion of atypical symptoms may be higher than with a first MI, and particular attention is needed in the elderly, people with diabetes, and women. Subsequent MI due to stent thrombosis tends to present with very sudden and severe symptoms because of abrupt blockage of blood flow. In hospitalized patients, a sudden drop in blood pressure, decreased oxygen saturation, or ECG changes may be the first sign of a new MI.


7. Signs

The physical signs of subsequent myocardial infarction follow the same pattern as a first MI. Sweating, pallor, tachycardia, abnormal blood pressure, S3/S4 gallop rhythm, and new heart murmurs (mitral regurgitation due to papillary muscle rupture, ventricular septal defect) may appear. When a new MI occurs while heart failure already exists from a previous MI, the risk of pulmonary edema and cardiogenic shock from rapid worsening of heart failure is higher than with a first MI.

The most important diagnostic clue is new ECG changes. When new ST elevation, new left bundle branch block, or new ST depression is identified compared with the previous ECG, immediate evaluation and activation of reperfusion are needed. However, a major diagnostic challenge is that new changes are difficult to distinguish when ECG changes from the previous MI (Q waves, T-wave inversion, ST changes) already exist. In this case, serial changes in troponin play a decisive role.


8. Screening

Early detection of subsequent myocardial infarction takes place in two contexts. First is early detection in hospitalized patients. In patients hospitalized for a previous MI, when symptom changes occur (worsening or recurrence of chest pain, worsening dyspnea, hemodynamic instability), a 12-lead ECG and high-sensitivity troponin are repeated immediately. Continuous ECG monitoring (in the CCU or cardiac ward) is important for this purpose.

Second is detection of recurrence in outpatient follow-up after discharge. Through patient education after discharge, patients are instructed to visit the emergency department immediately with new chest pain or worsening symptoms. In outpatient follow-up, residual ischemia is evaluated with echocardiography (left ventricular function, presence of new wall motion abnormalities) and, if needed, stress imaging (exercise ECG, stress echocardiography, nuclear perfusion imaging, cardiac CT angiography). When complete revascularization has not been achieved, planning staged PCI for residual lesions is key to preventing recurrent MI.


9. Diagnosis

The diagnostic criterion for subsequent myocardial infarction (I22) is defined as a new myocardial infarction occurring within 28 days after a previous AMI. The key to diagnosis is a new rise after confirmation of a rising-then-falling pattern of troponin (rising and falling pattern, a new troponin rise distinguishable from the previous MI). When a further rise (an increase of at least 20%) is confirmed while high-sensitivity troponin is already elevated, it suggests new myocardial injury.

On the ECG, new ST segment changes, new Q wave formation, and new left bundle branch block aid diagnosis. However, ECG changes from the existing MI may make interpretation difficult. On echocardiography, a wall motion abnormality in a new region supports a new myocardial infarction. Coronary angiography is essential for identifying the anatomical cause of reinfarction (stent thrombosis vs. new lesion occlusion) and performing immediate PCI. Cardiac MRI is the best for accurately evaluating a new infarct region by distinguishing it from existing infarct scar.


10. Treatment

The treatment principles for subsequent myocardial infarction are the same as for a first acute myocardial infarction. When new ST segment elevation is confirmed (subsequent STEMI), immediate primary PCI is the top priority. When stent thrombosis is suspected at a previously stented site, after confirmation by emergency coronary angiography, aspiration thrombectomy and placement of a new stent are considered. In this situation, intravenous cangrelor can be used for immediate platelet inhibition.

Readjustment of antiplatelet therapy is needed. If the patient was taking clopidogrel, switching to ticagrelor or prasugrel is considered based on CYP2C19 genetic test results or empirical judgment. If complete revascularization was not previously achieved, PCI of remaining significant lesions is also planned at this opportunity. When a new MI occurs while left ventricular function is already reduced, an intra-aortic balloon pump (IABP) or mechanical circulatory support devices (Impella, ECMO) should be prepared in case of cardiogenic shock. Medical therapy after discharge follows the principles of secondary prevention, but because the risk of recurrence is higher, addition of a PCSK9 inhibitor, longer DAPT, and the like are actively considered.


11. Prognosis

The prognosis of subsequent myocardial infarction is markedly poorer than that of a first AMI. The 30-day in-hospital mortality of recurrent MI reaches 2~3 times that of a first MI, because additional myocardial loss occurs on top of existing cardiac dysfunction. The risks of cardiogenic shock and ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation) are markedly higher than with a first MI. The prognosis of recurrent MI is particularly poor in elderly patients, patients with diabetes, and patients with multivessel disease.

In the long term, prognosis worsens in inverse proportion in patients with repeated recurrences. In one study, the 6-year cumulative mortality of patients with recurrent MI was more than twice that of first MI. The degree of preservation of left ventricular function (LVEF) is the strongest long-term prognostic predictor. Thorough implementation of complete revascularization and optimal medical therapy (DAPT, high-intensity statin, ACE inhibitor, beta-blocker) can significantly reduce the risk of recurrence and mortality.


12. Prevention

Thorough secondary prevention is key to preventing subsequent myocardial infarction. Dual antiplatelet therapy (aspirin + ticagrelor or prasugrel) is maintained for 12 months, after which long-term single antiplatelet therapy is continued in high-risk patients. Because poor adherence is the strongest risk factor for recurrence, patient education and medication management are absolutely important. LDL-C <55mg/dL is achieved with high-intensity statins, and a PCSK9 inhibitor is added if the target is not reached.

Beta-blockers (with reduced LVEF or symptoms) and ACE inhibitors/ARBs (with LVEF <40%, diabetes, kidney disease, or hypertension) are taken long term. Colchicine (0.5mg once daily) can be considered, as its effect in reducing the risk of recurrent MI through suppression of residual cardiovascular inflammation was confirmed in the COLCOT trial. When complete revascularization (PCI/CABG of remaining significant stenoses) has not been achieved, staged complete revascularization is planned. Cardiac rehabilitation programs are effective for reducing recurrent cardiovascular events, restoring exercise tolerance, and providing psychological support, and are recommended for all MI survivors.


13. References

  1. Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. European Heart Journal. 2015;36(19):1163-1170. DOI: 10.1093/eurheartj/ehu505. PMID: 25537195.

  2. Borrayo-Sanchez G, Madrid-Miller A, Arriaga-Nava R, et al. When more means less: the prognosis of recurrent acute myocardial infarctions. PLoS ONE. 2021;16(12):e0261109. DOI: 10.1371/journal.pone.0261109. PMID: 34879101.

  3. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023;44(38):3720-3826. DOI: 10.1093/eurheartj/ehad191. PMID: 37622654.

  4. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine. 2009;361(11):1045-1057. DOI: 10.1056/NEJMoa0904327. PMID: 19717846.

  5. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine. 2017;376(18):1713-1722. DOI: 10.1056/NEJMoa1615664. PMID: 28304224.

  6. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. New England Journal of Medicine. 2020;383(19):1838-1847. DOI: 10.1056/NEJMoa2021372. PMID: 32865380.

  7. Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. New England Journal of Medicine. 2019;381(21):2032-2042. DOI: 10.1056/NEJMoa1908419. PMID: 31556978.

  8. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835-842. DOI: 10.1001/jama.284.7.835. PMID: 10938172.

  9. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapentaenoic acid for hypertriglyceridemia. New England Journal of Medicine. 2019;380(1):11-22. DOI: 10.1056/NEJMoa1812792. PMID: 30415628.

  10. Lopes JP, Teixeira R, Lourenco C, et al. Prognosis following acute myocardial infarction. European Heart Journal. 2025;46(16):1551-1560. DOI: 10.1093/eurheartj/ehae810. PMID: 39718019.